TCT 2025: ShortCUT Trial Compares Cutting Balloon Angioplasty and Intravascular Lithotripsy (IVL) for Calcified Coronary Artery Disease
This news is covered by the Medical Dialogues Bureau present at the TCT Conference 2025, being held in San Francisco, USA.
Cutting balloon angioplasty was found to be non-inferior to intravascular lithotripsy (IVL) in achieving optimal stent expansion for patients with moderate-to-severely calcified coronary lesions undergoing percutaneous coronary intervention (PCI), according to results of the ShortCUT trial.
The study also found that cutting balloon angioplasty offered similar procedural and clinical outcomes at a significantly lower procedural cost.
The ShortCUT trial is the first adequately powered, randomized controlled trial to compare intravascular lithotripsy to other balloon-based device for the treatment of calcified coronary artery disease.
No direct quote available.
Author's summary: TCT 2025 presents ShortCUT trial results comparing cutting balloon angioplasty and IVL.
More News
- Nick Offerman and Lee K. Buchanan Close Out Arts and Humanities Day with a Love Letter to Carpentry, Family, and the Pursuit of Hands-On Work in the Digital Age
- The Angel Ball Honors Tina Knowles
- Keurig Dr Pepper Shares Updates For Plan To Split Into 2 Companies
- Atalanta 1-1 AC Milan: Rossoneri up to second in Serie A while hosts remain unbeaten
- Loveland to continue LRC overnight shelter while seeking permanent site
- Looking back: Local ghost legends